Y mAbs Therapeutics


Prices are adjusted according to historical splits.

Y mAbs Therapeutics Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$356.85 million
Book Value:
Revenue TTM:
$75.03 million
Operating Margin TTM:
Gross Profit TTM:
$57.70 million
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Y mAbs Therapeutics had its IPO on 2018-09-21 under the ticker symbol YMAB.

The company operates in the Healthcare sector and Biotechnology industry. Y mAbs Therapeutics has a staff strength of 147 employees.

Stock update

Shares of Y mAbs Therapeutics opened at $7.92 at the start of the last trading session i.e. 2023-06-03.

The stocks traded within a range of $7.56 - $8.18, and closed at $8.17.

This is a +5.01% increase from the previous day's closing price.

A total volume of 274,600 shares were traded at the close of the day’s session.

In the last one week, shares of Y mAbs Therapeutics have slipped by -15.07%.

Y mAbs Therapeutics's Key Ratios

Y mAbs Therapeutics has a market cap of $356.85 million, indicating a price to book ratio of 2.056 and a price to sales ratio of 5.2098.

In the last 12-months Y mAbs Therapeutics’s revenue was $75.03 million with a gross profit of $57.70 million and an EBITDA of $-57817000. The EBITDA ratio measures Y mAbs Therapeutics's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Y mAbs Therapeutics’s operating margin was -78.16% while its return on assets stood at -22.32% with a return of equity of -55.7%.

In Q1, Y mAbs Therapeutics’s quarterly earnings growth was a positive 0% while revenue growth was a positive 93.1%.

Y mAbs Therapeutics’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-1.6 per share while it has a forward price to earnings multiple of 119.0476 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Y mAbs Therapeutics’s profitability.

Y mAbs Therapeutics stock is trading at a EV to sales ratio of 2.5226 and a EV to EBITDA ratio of -0.8522. Its price to sales ratio in the trailing 12-months stood at 5.2098.

Y mAbs Therapeutics stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$137.45 million
Total Liabilities
$25.92 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Y mAbs Therapeutics ended 2023 with $137.45 million in total assets and $0 in total liabilities. Its intangible assets were valued at $137.45 million while shareholder equity stood at $107.83 million.

Y mAbs Therapeutics ended 2023 with $0 in deferred long-term liabilities, $25.92 million in other current liabilities, 4000.00 in common stock, $-442433000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $92.63 million and cash and short-term investments were $92.63 million. The company’s total short-term debt was $855,000 while long-term debt stood at $0.

Y mAbs Therapeutics’s total current assets stands at $124.01 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $18.70 million compared to accounts payable of $8.84 million and inventory worth $8.95 million.

In 2023, Y mAbs Therapeutics's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Y mAbs Therapeutics paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Y mAbs Therapeutics stock is currently trading at $8.17 per share. It touched a 52-week high of $20.48 and a 52-week low of $20.48. Analysts tracking the stock have a 12-month average target price of $12.71.

Its 50-day moving average was $6.85 and 200-day moving average was $7.63 The short ratio stood at 3.99 indicating a short percent outstanding of 0%.

Around 1234.3% of the company’s stock are held by insiders while 6180.8% are held by institutions.

Frequently Asked Questions About Y mAbs Therapeutics

The stock symbol (also called stock or share ticker) of Y mAbs Therapeutics is YMAB

The IPO of Y mAbs Therapeutics took place on 2018-09-21

Similar Industry Stocks (Biotechnology)

Last Price

Most Active

Last Price
Zomato Limited (ZOMATO)
Tesla Inc (TSLA)
Yes Bank Limited (YESBANK)

Top Gainers

Last Price
AEye Inc (LIDRW)

Top Losers

Last Price


Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody which has completed pivotal phase 2 clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, and Omburtamab 03-133 that is in phase 1 clinical trials for the treatment of intrathecal immunotherapy for CNS/leptomeningeal metastases. In addition, its product pipeline includes huB7-H3 for the treatment of systemic solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.


230 Park Avenue, New York, NY, United States, 10169